StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

Lipocine price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Lipocine's price to sales ratio was 8.4× on Nov 11, 2026, against 4.3× a year earlier. Over the last 5 years it ranged from 1.5× to 376.0×, with a median of 11.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.4×−1.7
2025Dec 31, 202510.1×+6.8
2024Dec 31, 20243.3×−239.5
2023Oct 31, 2023242.8×+237.9
2022Apr 29, 20224.8×−121.5
2020Apr 30, 2020126.4×+68.0
2019Dec 31, 201958.4×−6.4
2018Dec 31, 201864.8×–

More Lipocine figures

See a number that looks wrong?